Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.
Authors
- Charles L. Loprinzi (ORCID: https://orcid.org/0000-0001-8044-5752)
- Paul J. Novotny (ORCID: https://orcid.org/0000-0002-1526-9817)
- Jones T. Nauseef (ORCID: https://orcid.org/0000-0003-2302-4171)
- Bradley J. Stish (ORCID: https://orcid.org/0000-0003-2752-0607)
- Michael Humeniuk
- Christopher H. Chay
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
- Thomas J. Smith (ORCID: https://orcid.org/0000-0002-0978-1494)
- Andrew Jonathan Huang
- Kathryn Ruddy
- Selina Lai-ming Chow (ORCID: https://orcid.org/0009-0007-5897-8107)
- D.A. Diaz Pardo
- Gina L. Mazza
- Scott T. Tagawa
- Cindy Tofthagen (ORCID: https://orcid.org/0000-0002-3757-5823)
- Kushal Naha
- Lucile L. Adams-Campbell
Institutions
- Mayo Clinic (US)
- Cornell University (US)
- Jacksonville College (US)
- Yale University (US)
- University of Chicago (US)
- Regional Cancer Center (US)
- Mayo Clinic in Arizona (US)
- Cancer Research Center (US)
- Spartanburg Regional Healthcare System (US)
- Rocky Mountain Cancer Centers (US)
- Aspirus Wausau Hospital (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Weill Cornell Medicine (US)
- Georgetown Lombardi Comprehensive Cancer Center
- The Ohio State University (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1200/jco-25-01486
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 36.44